AU777218B2 - Staphyloccocus aureus antigen-containing whole cell vaccine - Google Patents

Staphyloccocus aureus antigen-containing whole cell vaccine Download PDF

Info

Publication number
AU777218B2
AU777218B2 AU49950/00A AU4995000A AU777218B2 AU 777218 B2 AU777218 B2 AU 777218B2 AU 49950/00 A AU49950/00 A AU 49950/00A AU 4995000 A AU4995000 A AU 4995000A AU 777218 B2 AU777218 B2 AU 777218B2
Authority
AU
Australia
Prior art keywords
antigen
staphylococcus aureus
cell
type
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49950/00A
Other languages
English (en)
Other versions
AU4995000A (en
Inventor
Ali I. Fattom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Nabi Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals Inc filed Critical Nabi Biopharmaceuticals Inc
Publication of AU4995000A publication Critical patent/AU4995000A/en
Assigned to NABI BIOPHARMACEUTICALS reassignment NABI BIOPHARMACEUTICALS Change of Name of Applicant under S 104 Assignors: NABI
Application granted granted Critical
Publication of AU777218B2 publication Critical patent/AU777218B2/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA Assignment by Patentee under S 187, Reg 19.1 Assignors: NABI BIOPHARMACEUTICALS
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
AU49950/00A 1999-05-10 2000-05-10 Staphyloccocus aureus antigen-containing whole cell vaccine Ceased AU777218B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/307775 1999-05-10
US09/307,775 US6294177B1 (en) 1996-09-11 1999-05-10 Staphylococcus aureus antigen-containing whole cell vaccine
PCT/US2000/012589 WO2000067785A2 (fr) 1999-05-10 2000-05-10 Vaccin a cellules entieres contenant l'antigene de staphylococus aureus

Publications (2)

Publication Number Publication Date
AU4995000A AU4995000A (en) 2000-11-21
AU777218B2 true AU777218B2 (en) 2004-10-07

Family

ID=23191126

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49950/00A Ceased AU777218B2 (en) 1999-05-10 2000-05-10 Staphyloccocus aureus antigen-containing whole cell vaccine

Country Status (15)

Country Link
US (2) US6294177B1 (fr)
EP (1) EP1178824B1 (fr)
JP (1) JP2002544169A (fr)
AT (1) ATE337015T1 (fr)
AU (1) AU777218B2 (fr)
BR (1) BR0010478A (fr)
CA (1) CA2372633C (fr)
CY (1) CY1105744T1 (fr)
DE (1) DE60030274T2 (fr)
DK (1) DK1178824T3 (fr)
ES (1) ES2270835T3 (fr)
MX (1) MXPA01011507A (fr)
NZ (1) NZ515394A (fr)
PT (1) PT1178824E (fr)
WO (1) WO2000067785A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
MXPA03011701A (es) * 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
CA2474458A1 (fr) * 2002-01-31 2003-08-07 Mitchell C. Sanders Methode de detection de micro-organismes
JP4304077B2 (ja) * 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド 微生物感染の処置のための組成物および方法
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
PL229487B1 (pl) * 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
KR101359930B1 (ko) 2004-09-22 2014-02-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
WO2006135912A2 (fr) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Utilisation de leucocidine de panton valentine pour le traitement et la prevention d'infections causees par le staphylococcus
SG170090A1 (en) * 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
CA2655133C (fr) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Utilisation de toxine alpha pour le traitement et la prevention d'infections par le staphylocoque
US20080170996A1 (en) * 2006-07-28 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and Methods for Stimulation of Lung Innate Immunity
EP2161035B1 (fr) * 2007-05-28 2019-08-21 Daiichi Sankyo Company, Limited Composition de vaccin à cellules entières contenant bordetella parapertussis
EP2175880A1 (fr) * 2007-07-23 2010-04-21 Vaccine Research International PLC Vaccin à cellules entières staphylococciques inactivées
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2731384C (fr) 2008-07-21 2015-03-10 The Brigham And Women's Hospital, Inc. Procedes et compositions se rapportant a des beta-1,6-glucosamine oligosaccharides synthetiques
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US20110105383A1 (en) * 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
BRPI0920041A2 (pt) 2008-10-06 2017-06-27 Univ Chicago composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
BRPI1010307B1 (pt) 2009-04-03 2021-07-27 University Of Chicago Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102971009A (zh) 2009-10-30 2013-03-13 诺华有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN104768572B (zh) 2012-04-26 2021-08-24 芝加哥大学 葡萄球菌凝固酶抗原及其使用方法
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016044839A2 (fr) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions et méthodes pour traiter des infections virales par le biais de l'immunité innée stimulée en combinaison avec des composés antiviraux
EP3229833A1 (fr) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Procédé de traitement
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections
WO2019055620A1 (fr) * 2017-09-13 2019-03-21 Stc. Unm Répliques de cellule silicifiées, procédés de fabrication et procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010788A1 (fr) * 1996-09-11 1998-03-19 Nabi ANTIGENE DE $i(STAPHYLOCOCCUS AUREUS)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345864A1 (de) 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
NZ216119A (en) 1985-05-13 1989-01-06 Commw Scient Ind Res Org Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010788A1 (fr) * 1996-09-11 1998-03-19 Nabi ANTIGENE DE $i(STAPHYLOCOCCUS AUREUS)

Also Published As

Publication number Publication date
US6294177B1 (en) 2001-09-25
ES2270835T3 (es) 2007-04-16
AU4995000A (en) 2000-11-21
CA2372633A1 (fr) 2000-11-16
CY1105744T1 (el) 2010-12-22
MXPA01011507A (es) 2002-11-07
PT1178824E (pt) 2007-01-31
EP1178824B1 (fr) 2006-08-23
US20020031528A1 (en) 2002-03-14
US6537559B2 (en) 2003-03-25
WO2000067785A2 (fr) 2000-11-16
DE60030274D1 (de) 2006-10-05
WO2000067785A3 (fr) 2001-02-08
JP2002544169A (ja) 2002-12-24
NZ515394A (en) 2004-11-26
ATE337015T1 (de) 2006-09-15
DK1178824T3 (da) 2006-10-09
CA2372633C (fr) 2010-03-30
EP1178824A2 (fr) 2002-02-13
DE60030274T2 (de) 2008-01-10
BR0010478A (pt) 2002-05-21

Similar Documents

Publication Publication Date Title
AU777218B2 (en) Staphyloccocus aureus antigen-containing whole cell vaccine
US6194161B1 (en) Staphylococcus aureus antigen
CA2366433C (fr) Antigene et vaccin de staphylocoque
AU754890B2 (en) Enterococcus antigens and vaccines
MXPA00003674A (en) Enterococcus antigens and vaccines

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: NABI BIOPHARMACEUTICALS

Free format text: FORMER NAME: NABI